Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMF biomarker-guided comparison of cyclosporine and dupilumab in pediatric atopic dermatitis
NL-OMON54541Recruiting
- Sponsor
- Erasmus MC
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Peptides
- Countries
- 1
01
Overview
Randomised, open-label trial of cyclosporine and dupilumab in atopic dermatitis (AD) (3 arms), sponsored by Erasmus MC. Primary endpoint: Eczema Area and Severity Index at 6 months. Started Aug 2021; status: recruiting.
02
Drugs
cyclosporinedupilumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON54541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54541.